Developing a Plasmodium vivax vaccine

by Prof. Manuel Elkin Patarroyo | 19 MAY 2018

developing a plasmodium vivax vaccine
 Image used for representational purpose only



Organised by PC2 Scientific Services the symposium aims to enable a wider platform for Pharma & Biotech in Hyderabad


Hyderabad, May 19, 2018: “Chemically synthesized vaccines could be the future as they are economical, quicker to produce, reproducible and do not need high-end infrastructure like cold storage”, said the keynote speaker, the Columbian malaria vaccine scientist Dr. Manuel Elkin Patarroyo M during his distinguished lecture “The New Vaccines” on May 19, 2018, at CR RAO AIMSCS, University of Hyderabad at the one-day symposium on Vaccines.


The symposium was organized by PC2 Scientific Services, the Hyderabad based strategic and technical consulting company in association with Federation of Asian Biotech Associations (FABA) and CR RAO AIMSCS to create awareness and generate more insight on Research and Development of Vaccines: Issues, Challenges, and Opportunities. The event was well attended by many dignitaries from the scientific - research & academic and industry sectors both from India and overseas.


The symposium was presided by Professor Dr. Manuel Elkin Patarroyo M. who first created the chemically synthesized vaccine (SPf66) against the scourging disease, Malaria, followed by a large series of clinical and field trials in different parts of the world that allowed the conclusion of the feasibility of chemically synthesized vaccines. The vaccine was the first-of-its-kind against a parasite and the first one to be produced in a third-world country. Professor Dr. Manuel donated the SPf66 patent to the World Health Organization in 1995 to ensure a cheap and accessible cure for people in developing countries.


Malaria, the disease has been a growing concern across the world. Malaria cases have been increasingly high in some parts of the Americas, South-East Asia, Western Pacific and Africa, although in many other regions infections are stable or going down. A recent study says, there were 216 million cases of malaria in 91 countries, an increase of five million compared with 2015. The World Health Organization estimates that malaria killed 445,000 people in 2016. The economies investing on resources and preventive action towards clinical and medical innovation ecosystem.


Speaking on this occasion, Dr. Dasari V Ravi Kumar, Director of PC2 Scientific Services adds, our city Hyderabad is producing about 33 per cent of global vaccines dosages and 35 per cent to the pharmaceutical production in the country. AlsoI would also like to emphasise on the commendable role the Govt. of Telangana for understanding the need and providing resources to create large-scale facilities, R&D and production houses. Through this initiative, we aim to bring international scientific expert delegation and to create wider opportunities in Hyderabad to promote research on affordable and accessible clinical innovations”.


Some of the eminent speakers include Prof. Dr. Manuel Alfonso Patarroyo (Professor, School of Medicine and Health Sciences, Universidad del Rosario, Colombia) and other important speakers from the industry which included:


             Dr. Anand Kumar, CEO, Indian Immunologicals


             Dr. Akshay Goel, Senior Vice President - R&D, Biological E limited


             Dr. Partha Kumar Sarkar, Associate Vice President, ShanthaBiotechnics- A Sanofi Company


             Dr. Dilip Mathai, Dean, Apollo Institute of Medical Sciences and Research, Hyderabad, India


             Dr. Sunil Gairola, Director (Quality Control), Serum Institute of India Pvt. Ltd.


             Dr. M Kuppusamy, Managing Director, Tergene Biotech


             Dr. Chisty Basha, United States Pharmacopeia - India


             Dr. T.S. Rao, Senior Adviser, DBT, New Delhi


             Dr. Anand Govindalur, CEO, Govin Capital, Singapore & Startup Accelerator India Pvt. Ltd.


             Dr. Uday Saxena, Co-Founder, Kareus Therapeutics

 Disclaimer: Welthi.com does not guarantee any specific results as a result of the procedures mentioned here, and the results may vary from person to person. Read more
Epione provides relief with latest non surgical minimally invasive procedures using Regenerative Therapy

Epione provides relief with latest non surgical ...

Epione Center for Pain Relief and Beyond - a one o...
KIMS Basic Trauma Course 2019

KIMS Basic Trauma Course 2019

The Department of Orthopaedics at KIMS Hospitals, ...
KIMS Hospitals conducts continuous medical education on Trans Cranial Direct Current Stimulation (TDCS)

KIMS Hospitals conducts continuous medical ...

KIMS in association with the NIMHANS, JIPMER and S...


Yes, we love the idea of deep fried bhajjis and sa...
Unknown Facts about Post mastectomy Breast Reconstruction

Unknown Facts about Post mastectomy Breast ...

Breast Cancer is the most common malignancy occurr...
Wish For A Monsoon Proof Skin

Wish For A Monsoon Proof Skin

During the Monsoon, the skin is more prone to fung...
World Stroke Day 29th Oct 2018

World Stroke Day 29th Oct 2018

A stroke is defined as an abrupt onset of a neurol...
Hyderabad Doctors successfully perform Asia's First Transcatheter Tricuspid Valve Replacement procedure

Hyderabad Doctors successfully perform Asia's ...

Only 40 such surgeries reported around the world...
SuVitas Launches Bangalore’s First Dedicated Transition Care Facility

SuVitas Launches Bangalore’s First Dedicated ...

Catering to a need for post critical care that has...
Itermittent Fasting: The How s and Why's

Itermittent Fasting: The How s and Why's

Intermittent Fasting is the latest global fitness ...
Our responsibility to our emotions

Our responsibility to our emotions

In this world, there are all kinds of people. Some...
Eyes show you the world

Eyes show you the world

With increasing rate of air pollution, the ways it...